Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE – Get a rating) EVP Erik Harris sold 295 shares in a trade that took place on Sunday, June 19. The stock was sold at an average price of $54.78, for a total value of $16,160.10. Following the transaction, the executive vice president now owns 36,160 shares of the company, valued at approximately $1,980,844.80. The sale was disclosed in a filing with the Securities & Exchange Commission, available at this link.
Ultragenyx Pharmaceutical stock traded down $0.55 during Wednesday’s trading, hitting $56.12. 390,940 shares of the company were traded, against an average volume of 492,969. Ultragenyx Pharmaceutical Inc. has a 52-week low of $45.20 and a 52-week high of $104.38. The company has a market capitalization of $3.92 billion, a P/E ratio of -8.17 and a beta of 1.61. The stock’s 50-day simple moving average is $58.86 and its two-hundred-day simple moving average is $68.30.
Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last reported quarterly earnings data on Thursday, May 5. The biopharmaceutical company reported ($2.19) EPS for the quarter, missing analyst consensus estimates of ($1.76) by ($0.43). The company posted revenue of $79.94 million for the quarter, compared to analysts’ expectations of $84.25 million. Ultragenyx Pharmaceutical posted a negative return on equity of 49.18% and a negative net margin of 141.65%. The company’s quarterly revenue fell 19.6% from the same quarter last year. During the same quarter of the previous year, the company posted an EPS of ($2.03). Equity research analysts expect Ultranyx Pharmaceutical Inc. to post -7.15 earnings per share for the current year.
You have never heard of this rare metal. But it is CRITICAL for our fighter planes, our missiles and our military vehicles. The bad news is that communist China has a MONOPOLY on this essential resource…
A number of equity analysts have published reports on RARE stocks. Credit Suisse Group upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “outperforming” rating and raised its price target for the stock from $99.00 to $105.00 in a Wednesday 16 research report. march. Cowen lowered his price target on Ultragenyx Pharmaceutical from $124.00 to $99.00 in a Friday, May 6 research report. Piper Sandler lowered her price target on Ultragenyx Pharmaceutical from $170.00 to $135.00 and set an “overweight” rating on the stock in a Wednesday, May 18 research report. Cowen reduced his target price on Ultragenyx Pharmaceutical from $124.00 to $99.00 in a Friday, May 6 research report. To finish, StockNews.com downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday. Two investment analysts gave the stock a sell rating, three gave the company a hold rating and eight gave the company a buy rating. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Hold” and a consensus target price of $111.29.
A number of hedge funds have recently bought and sold shares of RARE. New Jersey State Joint Pension Fund D increased its stake in shares of Ultragenyx Pharmaceutical by 0.4% in the fourth quarter. New Jersey State Joint Pension Fund D now owns 42,284 shares of the biopharmaceutical company valued at $3,556,000 after buying 152 more shares last quarter. Arizona State Retirement System increased its stake in shares of Ultragenyx Pharmaceutical by 0.9% in the first quarter. Arizona State Retirement System now owns 17,504 shares of the biopharmaceutical company valued at $1,271,000 after buying 159 additional shares last quarter. CIBC Asset Management Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 6.0% in the fourth quarter. CIBC Asset Management Inc. now owns 2,908 shares of the biopharmaceutical company valued at $245,000 after purchasing an additional 164 shares last quarter. Wetherby Asset Management Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 4.3% in the fourth quarter. Wetherby Asset Management Inc. now owns 4,956 shares of the biopharmaceutical company valued at $417,000 after buying 204 more shares last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Ultragenyx Pharmaceutical by 6.1% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,892 shares of the biopharmaceutical company valued at $283,000 after buying an additional 225 shares last quarter. 97.49% of the shares are held by institutional investors.
Ultragenyx Pharmaceutical Company Profile (Get a rating)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Read more
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Ultragenyx Pharmaceutical right now?
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.
Although Ultragenyx Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here
